, where Val L and Ala L denote the lanthionine amino acid ends linked via a monosulfide bridge to form the lanthionine structure, was synthesized. It was found to possess selectivity for and potency at the ␦ versus opioid receptor as defined by binding studies and by its respective activity on the mouse vas deferens compared with the guinea pig ileum. The agent produced a potent analgesia after intrathecal and intraperitoneal delivery with ED 50 values being, respectively, 0.19 g and 0.49 mg/kg. The effects of the agent were reversed by the ␦-selective antagonist naltrindole. These analgesic actions occurred at doses that had no effect upon general behavior or motor function. These results suggest a potent ␦-preferring agent suitable for development as a systemic ␦ opioid analgesic.
Agents that interact as agonists at the receptor produce a potent analgesia. Studies with intracerebral and intrathecal delivery have demonstrated that these effects are mediated by opioid binding sites in the brain and in the spinal cord in animals and in humans (Yaksh, 1997) . Similarly, systemic delivery of agents known to cross the blood-brain barrier, e.g., the opioid alkaloids morphine and its congeners, will yield a potent antinociception that displays a pharmacology expected for receptors. The clinical relevance of this systemic activity is well appreciated and to date receptor agonists represent the mainstay of systemic pain therapy in humans. Comparable studies with ␦ opioid agonists have similarly demonstrated that ␦ receptor-preferring agonists can produce a potent analgesia after intrathecal delivery (Tung and Yaksh, 1982; Porreca et al., 1987) . As the majority of ␦ opioids with selective affinity and efficacy for the ␦ site are peptides subject to poor blood-brain barrier penetration and relatively rapid degradation, the demonstration of the systemic activity of these agonists has been less rigorously approached. Recent efforts have been focused on developing ␦ opioid receptor agonists with an emphasis on nonpeptidic structures. Thus, molecules such as TAN-67 (Tseng et al., 1997) , SNC-80 (Bilsky et al., 1995) , and BW373U86 (Chang et al., 1993) have been reported to have selectivity and efficacy at the ␦ receptor and to show activity after systemic delivery. In our own work, after synthesizing a series of peptidomimetics containing enkephalin analogs and testing them for opioid activity and biostability (Baker et al., 2000; Goodman et al., 2001; Rew et al., 2002) LanEnk), that has significant ␦ selectivity and also in vivo activity. In this article, we report on the analgesic activities of this lanthionine enkephalin after systemic and intrathecal delivery.
Materials and Methods
These studies were carried out according to protocols approved by the Institutional Animal Care and Use Committee of the University of California, San Diego (La Jolla, CA).
Drug Synthesis

DV L
2 DA L 5 LanEnk (Fig. 1 ) was synthesized via preparation of the linear peptide, including the lanthanide-bridge on solid phase, followed by cyclization in solution. The final product was purified and analyzed by reverse-phase high-performance liquid chromatography (Rew et al., 2002) .
In Vivo Testing
Animals. Male Holtzman-Sprague-Dawley (275-375 g; Harlan Industries, Indianapolis, IN) were housed individually in cages and maintained on a 12-h light/dark cycle with free access to food and water. For intrathecal drug delivery, rats were implanted with lumbar i.t. polyethylene (PE10) catheters under halothane anesthesia, according to a modification of the procedure described by Yaksh and Ruby (1976) . Any rat that displayed a postsurgical neurological disorder (e.g., limb paralysis) was excluded from the experiment. Testing was carried out approximately 5 days after implantation.
Nociceptive Testing. To assess the thermal nociceptive response threshold, a paw thermal stimulator modeled after that described by Hargreaves et al. (1988) was used (Department of Anesthesiology, University of California, San Diego, La Jolla, CA). The specifics of the device construction and its operation have been published elsewhere (Dirig et al., 1997) . In brief, the device consists of a glass surface (maintained at 30°C) upon which the rats were placed individually in Plexiglas cubicles. The thermal nociceptive stimulus originates from a focused projection bulb that is mounted on a movable arm under the glass surface. The timer and the light source are stopped by a motion-sensitive photodiode that detected the elevation of the paw or after the passing of 20 s (cut-off).
Animals were assigned randomly to different treatment groups. Two baseline measurements of hindpaw withdrawal were made before and at 15, 30, 60, 90, and 120 min after the drug injection. At each time point, withdrawal latency in seconds represents the average of the left and right paw of each subject.
Behavioral Testing. To assess general effects upon behavior, each animal was examined for the presence of a blink reflex (evoked by lightly touching the cornea with a hair), a pinnae reflex (a twitch of the pinnae evoked by placing a probe in the auditory meatus), placing and stepping (placing of the paw after drawing the dorsum of the paw over an edge), and catalepsy (remaining immobile for 10 s after placing the fore paws on a 4-cm bar).
Drugs and Delivery. Intrathecal drugs were administrated in a total volume of 10 l with a gear-driven syringe pump, followed by 10 l of saline flush over a time period of 30 s. For systemic delivery, drugs were prepared to be delivered in a volume of 0.5 ml/100 g b.wt.
The agonists delivered were the agonist morphine sulfate (Malinckrodt) and the ␦ opioid, DV L 2 DA L 5 LanEnk (mol.wt. ϭ 584.67, derived as trifluoroacetic salt; mol.wt. ϭ 699.69). The antagonists employed were the nonspecific agent naloxone hydrochloride (Sigma-Aldrich, St. Louis, MO), the ␦-preferring antagonist naltrindole hydrochloride (NTI) (Sigma-Aldrich), or the -preferring antagonist D-Phe-CysTyr-D-Trp-Orn-Thr-Pen-Thr-NH 2 (CTOP) (Peninsula Laboratories, Belmont, CA). All peptides were dissolved in 20% cyclodextrin (Wacker Chemie GmbH, Mü nchen, Germany). Other agents were dissolved in physiological saline. NTI was administrated 10 min before the agonist based on preliminary studies showing that to coincide with the time of peak antagonism (unpublished data). In experiments involving i.t. or i.p. injections, 20% cyclodextrin was used as control vehicle.
In Vitro Bioassay
The guinea pig ileum (GPI) assay was performed as described previously (Yaksh et al., 1995) following procedures originally described by Paton (1957) , examining the dose-dependent effects of drugs on the electrically evoked contractions in a 20-ml organ bath. The mouse vas deferens (MVD) assay was performed as described previously (Yaksh et al., 1995) following procedures originally described by Henderson and colleagues (Henderson et al., 1972) , examining the dose-dependent effects of drugs on the electrically evoked contractions in a 20-ml organ bath. The results are standardized by expressing the reduction in tension obtained at each dose level as a percentage of the mean control tension. Semilogarithmic plots of percent inhibition as a function of drug concentration permitted determination of IC 50 . Each drug was examined on at least two runs of four baths each. Mean Ϯ S.E.M. are presented. Potency on the GPI was taken to reflect the activity of the agent, whereas the MVD potency reflected /␦ activity. A high-ratio GPI ED 50 /MVD ED 50 was taken as an indicator of ␦ preference (Lord et al., 1977) .
Enzymatic Degradation Study
Enzymatic degradation studies of DV L 2 DA L 5 LanEnk and [D-Pen 2 ,D-Pen 5 ]-enkephalin (DPDPE) were carried out using rat brain homogenates followed by the modified procedure (Wang, 1996) of existing assays (Berman et al., 1983) . The parent Leu-enkephalin was employed as the reference molecule since the enzymatic stabilities in homogenates and plasma has been extensively reported (Hambrook et al., 1976; Marks et al., 1977; Hui et al., 1981; Shibanoki et al., 1992) .
Typically, 5 mM peptide substrate solution in 5 mM Tris ⅐ HCl buffer (pH 7.2), including 1.26 mM Cbz-Tyr-OH as an internal standard was prepared. To 1.80 ml of rat brain homogenates (130 mg/ml in 50 mM Tris ⅐ HCl buffer, pH 7.2), 200 l of the peptide substrate solution was added, and the mixture was incubated at 37°C in a temperature-controlled, shaking water bath. Aliquots (250l) were removed at different time intervals over 24 h, and enzymatic activity was quenched using 10 l of trifluoroacetic acid. After centrifugation at 12,500 rpm for 15 min, the supernatant was removed and analyzed for the remaining intact peptide by high-performance liquid chromatography using a Vydac protein peptide C 18 column. The column dimensions were 4.5 ϫ 250 mm (90 Å silica, 5 m), and UV detection was carried out at 220 nm. A binary system of water and acetonitrile, both containing 0.1% trifluoroacetic acid, was used throughout in a gradient elution. Concentration-time profiles were analyzed by exponential fitting, assuming a pseudo-first-order degradation process. Half-lives (t 1/2 ) were calculated from the observed rate constant (k obs ) as 0.693/k obs .
Results
In vitro analysis
The IC 50 of these agents on the mouse vas deferens (␦) and guinea pig ileum () are presented in Table 1 . A ratio for guinea pig ileum/mouse vas deferens Ͼ1 demonstrates a preference for the ␦ opioid receptor site and Ͻ1 demonstrates a preference for the opioid receptor site. As indicated by the IC 50 ratios, morphine is a -preferring agent, whereas DV L 2 DA L 5 LanEnk is comparatively potent as a ␦-preferring agonist. (Fig. 2, top) . The magnitude of the increase in response latency after i.t. injection was shown to be dose-dependent (Fig. 2, bottom) . The ordering of potency for these two agents based on their calculated ED 50 values (Table 2) indicates the ␦ agent to be approximately 18 times more potent than morphine after intrathecal delivery.
Systemic Activity. The intraperitoneal injection of either morphine and DV L 2 DA L 5 LanEnk resulted in an increase in the thermal escape latency (Fig. 3, top) . The magnitude of the increase in response latency after i.t. injection was shown to be dose-dependent (Fig. 3, bottom) . The ordering of potency for these two agents based on their calculated ED 50 values (Table 2) indicates them to be approximately equiactive after intraperitoneal delivery.
Duration of Action
As indicated, both drugs were able to produce a significant dose-dependent increase in the thermal escape latency. To compare the durations of action resulting from a given analgesic action, the area under the time-effect curve was plotted versus the peak effect observed for each dose after i.t. or i.p. injection. As indicated in Figs. 4 and 5, after both intrathecal and systemic delivery, the duration of action for a given antinociceptive effect for DV L 2 DA L 5 LanEnk did not differ significantly from that observed with morphine. These observations suggested that the peptidomimetic possessed a sta- Table 2 . Each point presents the mean and S.E.M. of four to eight rats. LanEnk. ED 50 calculations are presented in Table 2 . Each point presents the mean and S.E.M. of four to eight rats. LanEnk. The effects of specific antagonists against systemic morphine were not examined.
Behavioral Effects
Over the range of the doses delivered intrathecally, neither agent produced a significant effect upon the motor function or general behavioral indices (placing, stepping, and righting). At the highest systemic doses employed, both morphine and DV L 2 DA L 5 LanEnk reduced the pinnae and blink responses. After systemic delivery, morphine displayed increasing catalepsy at doses less than those required to produce the block of the thermal escape. In contrast, DV L 2 DA L 5 LanEnk had no detectable effect upon the catalepsy endpoint (Table 4) .
Resistance of the Peptidomimetic Opioid to Metabolism
DV L
2 DA L 5 LanEnk, DPDPE, and Leu-enkephalin were incubated in rat brain homogenates solution (pH 7.2) at 37°C for 24 h. Leu-enkephalin displayed a rapid decline in concentration, with a t 1/2 ϭ 6.7 min. In contrast, DV L 2 DA L 5 LanEnk and DPDPE showed no detectable decline over this interval (Table 5) .
Discussion
␦ Opioid Receptor-Mediated Analgesia. Efforts to create a peptidomimetic structure with ␦ opioid properties has led to the synthesis of structures with significant ␦ opioid selectivity (Rew et al., 2002) . In the present work, we examined the intrathecal and systemic activity of one of these structures. As indicated, after intrathecal delivery, consistent with the presence of ␦ opioid receptors in the dorsal horn and the ability of (Besse et al., 1990 ) ␦ opioid agonists to inhibit the firing of dorsal horn nociceptive neurons (Dickenson et al., 1987) , this agent displayed a potent analgesic activity with a potency comparable to that of morphine. Importantly, these effects of the peptidomimetic were readily reversed by the competitive ␦ opioid receptor antagonist (naltrindole) (Drower et al., 1991) in antagonist doses that had no effect upon the antinociceptive activity of morphine. This in vivo pharmacology is thus consistent with a systemically active ␦ opioid agonist. Central Penetration. Although there is some evidence of a peripheral opioid action in the face of inflammation (Nagasaka et al., 1996) , minimal activity has been observed with ␦ ligands, and no such peripheral action has been hypothesized in models such as those employed here using an acute thermal escape. Further evidence that the effect of these drugs on this model is central is provided by the fact that both agents were several hundred times more active after i.t. compared with i.p. delivery.
After intrathecal delivery, the relative potency ratio suggested that the ␦ opioid agonist was more potent than morphine. In contrast, after systemic delivery, the agents were essentially equiactive. In the face of the metabolic stability of the peptide, these observations suggest that the peptide may experience a less efficient transfer across the blood-brain barrier than the alkaloid. These results are consistent with a variety of investigations that have considered the penetration of peptides through the blood-brain barrier. Previous reports with the systemic delivery of ␦-opioid-preferring peptides have shown that such agents indeed possess analgesic activity (Frederickson et al., 1983; Hansen et al., 1992) . In general, these agents appear to require considerably higher doses compared with a nonpeptide standard such as morphine. Many peptides show significant first-pass metabolism in the liver (Taki et al., 1998) . Why this lanthionine molecule displays this relative systemic potency is not clear. One possibility is that the lanthionine structures improve the metabolic stability (see below; Wang et al., 1996) as they make the molecule compact as opposed to a linear chain structure.
Metabolic Stability of Lanthionine Structures. The results of biostability tests indicate that both DV L 2 DA L 5 LanEnk and DPDPE are completely resistant to degradation in brain homogenates over the 24-h interval examined. The extraordinary resistance of these peptide analogs is likely due to the existence of the ␤,␤-dimethyl group in the position 2 or position 5 that stabilizes the compound toward enzymatic degradation (Fig. 1) . A previous study of enzymatic degradation for a similar lanthionine enkephalinamide LanEnk after systemic and intrathecal delivery may thus be explained in part by the biostability of the lanthionine structure.
␦ Opioid Analgesia. As noted in the Introduction, ␦ opioid receptor agonists have been repeatedly shown after intrathecal delivery to produce a potent analgesia in animal models. Development of a systemically active ␦ opioid agonist has potential virtues. Previous preclinical work has shown that in the face of tolerance with chronic opioid delivery, the action of the ␦ agonists is only marginally diminished, e.g., there is minimal cross-tolerance (Stevens and Yaksh, 1992) . The opioid agonists have a panoply of effects reflecting the association of receptors with neural systems that regulate respiratory function, arousal, and gastrointestinal activity to name a few. Using available agents and central delivery, it has been argued that the ␦ receptor may not play as important a role as the receptor in modulating the other functions that reflect the side-effect profile of all opioids. In humans, previous intrathecal studies with a ␦-preferring peptide (DADLE) has been shown to produce potent analgesia in cancer pain patients (Onofrio and Yaksh, 1983; Moulin et al., 1985) , whereas metkephamid, a modified pentapeptide, was shown earlier to have efficacy in postoperative pain after systemic delivery (Bloomfield et al., 1983) . The present studies afford initial data showing a systemically active ␦-preferring agonist with an analgesic potency comparable to that of morphine in this thermal escape model. These results provide an opportunity to assess the analgesic therapeutic ratio for the ␦ receptor compared with the receptor and to consider additional development of a therapeutically useful ␦ agonist. 
